Ascendis Pharma A/S vs Ionis Pharmaceuticals
ASND and IONS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASND and IONS compare
Ascendis Pharma A/S grew revenue faster over the last twelve months (113% versus −0.71% for Ionis Pharmaceuticals).
Ascendis Pharma A/S keeps more of each dollar of sales as profit, with a net margin of 70.8% compared with −56.9% at Ionis Pharmaceuticals.
Ascendis Pharma A/S scores higher on the StockData Score (7 against 4 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASND | IONS |
|---|---|---|
| Size and price | ||
| Market cap | – | $4.5B |
| Share price | $267.07 | $27.31 |
| Change, 1 year | 32.8% | −62.3% |
| Change, 5 years | 79.5% | −14.6% |
| Beta (5Y) | 0.75 | 0.65 |
| Employees | 879 | 1,402 |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 2 (better) | 0 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 4.7× |
| P/B | – | 11.5× |
| FCF yield | – | −13.6% |
| Fair value | – | $28.15 |
| Margin of safety | – | 3.0% |
| Growth | ||
| Revenue growth (TTM) | 113% (better) | −0.71% |
| Revenue growth, 5Y average | 153% (better) | 5.3% |
| Profitability | ||
| Gross margin | 91.3% | 98.2% (better) |
| Operating margin | 25.4% (better) | −58.8% |
| Net margin | 70.8% (better) | −56.9% |
| FCF margin | – | −64.2% |
| Return on equity | – | −108% |
| Financial health | ||
| Net debt / EBITDA | −1.61 | – |
| Interest coverage | 1.3× (better) | −29.4× |
| Current ratio | 2.99 | 5.43 (better) |
| Altman Z-score | – | 0.15 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 108% | 108% |
| Held by insiders | 0.83% | 0.80% |
| Insider net buying, 12 months | −$4.7M (better) | −$114M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 12.8% |
Go deeper
- ASND stock overview
- ASND income statement
- ASND valuation and score
- IONS stock overview
- IONS income statement
- IONS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.